Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05443633 · ClinicalTrials.gov registry record · NA
Enhancing Language Function in Aphasia
A NA study of Primary Progressive Aphasia and Aphasia, Acquired, sponsored by University of Arizona.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05443633: Recruiting NA study of Primary Progressive Aphasia and Aphasia, Acquired, sponsored by University of Arizona.
NCT05443633 is a NA study of Primary Progressive Aphasia and Aphasia, Acquired that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 30 participants, below the 91-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05443633, a NA study of Primary Progressive Aphasia and Aphasia, Acquired, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on the affected individuals and their families. Behavioral treatments that target language deficits have been shown to enhance overall communication skills and life satisfaction among individuals with aphasia. Although there is evidence that suggests that treatment is efficacious for individuals with aphasia, the extent of improvement long-term coupled with the neural patterns among those individuals are largely unknown. The current study aims to investigate the efficacy of language-based treatment and its corresponding neural patterns.
Primary Outcome
Mean change from baseline scores on the Boston Naming Test: Min score = 0; Max = 60; higher scores indicate better outcome
Conditions Studied
Interventions
- BEHAVIORAL individualized speech-language training
- BEHAVIORAL standard language intervention
Study Locations (1)
Arizona
- University of Arizona - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-30 |
| Est. Completion | 2028-12-15 |
| Phase | NA |
What NCT05443633 shows while recruiting
NCT05443633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 91-participant average among 15 other Primary Progressive Aphasia trials with a reported enrollment target (67% lower).
The record links to 4 conditions, with Primary Progressive Aphasia appearing as the primary indexed condition, and to 2 interventions - of which individualized speech-language training is the first listed.
NCT05443633 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT05443633 about?
NCT05443633 is a clinical study titled "Enhancing Language Function in Aphasia". Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million in...
What is the current status of trial NCT05443633?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-10-30. Estimated completion is 2028-12-15.
What conditions does trial NCT05443633 study?
This clinical trial studies the following conditions: Primary Progressive Aphasia, Aphasia, Acquired, Language Disorders, Stroke, Cerebrovascular.
What interventions are being tested in trial NCT05443633?
The interventions under investigation include: individualized speech-language training (BEHAVIORAL), standard language intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05443633?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05443633 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Progressive Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05443633's enrollment target sits among peer trials
30 10th of 15 higher than 6 of 15 other Primary Progressive Aphasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Progressive Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Language Function in Primary Progressive Aphasia
RECRUITING · NA
-
Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA
RECRUITING · NA
-
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
RECRUITING · NA
-
Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
ACTIVE NOT RECRUITING · NA
-
Treatment for Speech and Language in Primary Progressive Aphasia
ACTIVE NOT RECRUITING · NA
-
Communication Bridge Pilot Study
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI